Gelteq (GELS) Competitors $1.72 -0.03 (-1.71%) As of 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. ONCY, IMMX, VHAQ, ICCC, PYRGF, ANEB, RENB, ASRT, VTGN, and RPTXShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Oncolytics Biotech (ONCY), Immix Biopharma (IMMX), Viveon Health Acquisition (VHAQ), ImmuCell (ICCC), PyroGenesis Canada (PYRGF), Anebulo Pharmaceuticals (ANEB), Renovaro (RENB), Assertio (ASRT), VistaGen Therapeutics (VTGN), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Oncolytics Biotech Immix Biopharma Viveon Health Acquisition ImmuCell PyroGenesis Canada Anebulo Pharmaceuticals Renovaro Assertio VistaGen Therapeutics Repare Therapeutics Gelteq (NASDAQ:GELS) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership. Do institutionals & insiders hold more shares of GELS or ONCY? 6.8% of Oncolytics Biotech shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is GELS or ONCY more profitable? Gelteq's return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Oncolytics Biotech N/A -313.77%-130.19% Do analysts recommend GELS or ONCY? Oncolytics Biotech has a consensus price target of $4.33, indicating a potential upside of 380.95%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger earnings & valuation, GELS or ONCY? Gelteq has higher revenue and earnings than Oncolytics Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteq$100K162.37-$2.33MN/AN/AOncolytics BiotechN/AN/A-$23.14M-$0.29-3.11 Does the media refer more to GELS or ONCY? In the previous week, Oncolytics Biotech had 2 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score. Company Overall Sentiment Gelteq Neutral Oncolytics Biotech Neutral SummaryOncolytics Biotech beats Gelteq on 6 of the 10 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.52M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E RatioN/A21.5627.4020.04Price / Sales162.37281.10419.46118.60Price / CashN/A41.9536.6357.47Price / BookN/A7.518.085.67Net Income-$2.33M-$55.05M$3.16B$248.47M7 Day Performance-8.51%3.16%2.12%2.90%1 Month Performance-3.91%5.92%4.43%5.75%1 Year PerformanceN/A5.82%35.62%21.36% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.72-1.7%N/AN/A$16.52M$100K0.00N/AGap DownONCYOncolytics Biotech1.2363 of 5 stars$0.69+2.4%$4.33+528.0%-20.5%$63.54MN/A-2.3830IMMXImmix Biopharma3.3183 of 5 stars$2.21-1.3%$7.00+216.7%+23.0%$62.44MN/A-3.169VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeICCCImmuCell0.317 of 5 stars$6.14-10.8%N/A+55.9%$62.19M$26.49M-87.7070News CoverageGap DownHigh Trading VolumePYRGFPyroGenesis Canada0.0945 of 5 stars$0.33+1.8%N/A-35.5%$61.94M$9.14M-5.5390News CoverageANEBAnebulo Pharmaceuticals2.2378 of 5 stars$1.47-2.0%$5.50+274.1%-27.3%$61.63MN/A-5.654RENBRenovaro1.181 of 5 stars$0.36+0.4%N/A-82.0%$61.29MN/A-0.4620News CoverageGap UpASRTAssertio1.7416 of 5 stars$0.63-0.9%$2.75+335.5%-41.3%$61.03M$124.96M-1.9720Gap DownVTGNVistaGen Therapeutics1.3982 of 5 stars$2.03-2.9%N/A-38.7%$60.94M$490K-1.2240RPTXRepare Therapeutics2.1276 of 5 stars$1.37-3.5%$4.50+228.5%-55.6%$60.91M$53.48M-0.46180News Coverage Related Companies and Tools Related Companies Oncolytics Biotech Competitors Immix Biopharma Competitors Viveon Health Acquisition Competitors ImmuCell Competitors PyroGenesis Canada Competitors Anebulo Pharmaceuticals Competitors Renovaro Competitors Assertio Competitors VistaGen Therapeutics Competitors Repare Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
